Cosentyx vs Sotyktu
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Cosentyx | US Sotyktu | |
|---|---|---|
| Generic name | secukinumab | deucravacitinib |
| Drug class | IL-17A Inhibitor (Biologic) | TYK2 Inhibitor |
| Treats | Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis | Plaque psoriasis |
| Category | Autoimmune | Autoimmune |
| Manufacturer | Novartis | Bristol-Myers Squibb |
| Year approved | 2015 | 2022 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $160M | $130M |
| Common side effects | Respiratory infections, Inflammatory bowel disease, Fungal infections, Injection site reactions | Common cold symptoms, Increased infections, Cold sores, Mouth sores |
Frequently asked questions
Is Cosentyx or Sotyktu better?
Neither is universally "better." Cosentyx (secukinumab) and Sotyktu (deucravacitinib) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Cosentyx and Sotyktu?
Cosentyx is a IL-17A Inhibitor (Biologic) made by Novartis, while Sotyktu is a TYK2 Inhibitor made by Bristol-Myers Squibb. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Cosentyx has the larger estimated TV advertising budget of the two.